Carregant...
Inhibitor of Differentiation 1 (ID1) Facilitates the Efficacy of Sorafenib in Non-Small Cell Lung Cancer Cells through Suppressing Epithelial to Mesenchymal Transition
BACKGROUND: Sorafenib, which is a multitargeted kinase inhibitor, has shown some antitumor effects in patients with non-small cell lung cancer (NSCLC). However, the potential target of sorafenib’s antitumor activity is largely unknown. Moreover, definitive predictive biomarkers of benefit have rarel...
Guardat en:
| Publicat a: | Med Sci Monit |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
International Scientific Literature, Inc.
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7169441/ https://ncbi.nlm.nih.gov/pubmed/32275644 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.922148 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|